Veterinary BioBurden Testing Services Market Report 2026

The veterinary bioburden testing services market size has grown strongly in recent years. It will grow from $0.99 billion in 2025 to $1.07 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to increasing incidence of veterinary hospital acquired infections, reliance on manual microbial testing and culture methods, growing demand for sterilization validation in animal healthcare, expansion of veterinary pharmaceutical manufacturing quality control needs, rising awareness of hygiene standards in veterinary environments.

The veterinary bioburden testing services market size is expected to see strong growth in the next few years. It will grow to $1.49 billion by 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to integration of ai powered microbial risk prediction and analysis systems, expansion of automated and robotics driven laboratory testing platforms, increasing adoption of cloud based bioburden data management systems, stricter regulatory standards for veterinary sterilization and infection control, growing demand for rapid diagnostic and real time contamination monitoring solutions. Major trends in the forecast period include ai driven microbial contamination detection and predictive bioburden analytics, cloud based laboratory data management and sterilization compliance platforms, iot enabled real time environmental microbial monitoring systems, automated high throughput microbiological testing and robotic lab workflows, blockchain based sample traceability and contamination audit trail systems.

The growing incidence of zoonotic diseases is expected to propel the growth of the veterinary bioburden testing services market going forward. Zoonotic diseases refer to illnesses caused by pathogens that naturally spread between animals and humans through direct contact, contaminated food, water, or environmental exposure. The increasing incidence of zoonotic diseases is primarily driven by the expanding human-animal interface, as growing agricultural activities, wildlife encroachment, and livestock farming increase direct interactions between humans and animals, enabling pathogen spillover. The rising prevalence of zoonotic diseases increases demand for veterinary bioburden testing services as comprehensive microbial load assessment in animals becomes crucial to detect, monitor, and control pathogen reservoirs before transmission reaches human populations. For instance, in June 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, the number of West Nile virus disease cases, a major zoonotic arboviral disease transmitted from birds to humans through mosquitoes, increased from 1,132 cases in 2022 to 2,628 cases in 2023, representing a rise of 1,496 cases. Therefore, the growing incidence of zoonotic diseases is driving the growth of the veterinary bioburden testing services market.

The growth in livestock production is expected to propel the growth of the veterinary bioburden testing services market going forward. Livestock production refers to the raising and management of animals such as cattle, hogs, poultry, and sheep for food, fiber, and other agricultural products. The expansion of livestock production is mainly driven by rising global meat consumption, as increasing populations and higher income levels continue to boost demand for animal protein, encouraging producers to expand herd sizes and intensify farming activities. The growing scale and density of livestock operations increase the risk of microbial contamination and pathogen transmission, directly increasing the need for systematic bioburden monitoring and testing to maintain animal health and ensure food safety compliance. For instance, in July 2025, according to reports published by GOV. UK, a UK-based public sector information website, the UK’s total livestock output reached $23.42 billion (£20.1 billion) in 2024, marking a $1.28 billion (£1.1 billion) increase (5.6%) compared with 2023. Therefore, the growth in livestock production is driving the growth of the veterinary bioburden testing services market.

Leading companies operating in the veterinary bioburden testing services market are focusing on developing advanced solutions, such as AI-enabled microbial analysis platforms, to improve detection accuracy, shorten turnaround time, and enhance contamination assessment in animal healthcare and laboratory environments. AI-enabled microbial analysis refers to the application of artificial intelligence technologies to automatically identify, quantify, and classify microorganisms present in samples, supporting faster and more dependable testing outcomes. For instance, in May 2025, Carbgem, a Japan-based biotechnology company, launched Zone of Inhibition for Veterinary Medicine (ZOI VET), an advanced AI-integrated microbial detection solution developed to improve precision in contamination analysis. The solution utilizes automated image recognition and data analytics to efficiently detect and quantify microbial load, enabling veterinary laboratories and research facilities to strengthen quality control, maintain compliance with hygiene standards, and support improved infection prevention practices.

Major companies operating in the veterinary bioburden testing services market are Thermo Fisher Scientific Inc., Merck KGaA, Laboratory Corporation of America Holdings, Eurofins Scientific SE, SGS SA, Intertek Group plc, Charles River Laboratories International Inc., WuXi Biologics (Cayman) Inc., Element Materials Technology Group Limited, STERIS Laboratories Inc., WuXi AppTec Co. Ltd., Pace Analytical Services LLC, North American Science Associates Inc., Medistri SA, Microbac Laboratories Inc., Almac Group Limited, Boston Analytical Inc., Creative Bioarray, Pacific BioLabs Inc., Accuratus Lab Services Inc.

North America was the largest region in the veterinary bioburden testing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary bioburden testing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary bioburden testing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary bioburden testing services market consists of revenues earned by entities by providing services such as environmental monitoring, sterility testing, endotoxin testing, and microbial identification. The market value includes the value of related goods sold by the service provider or included within the service offering. The veterinary bioburden testing services market also includes sales of culture-based microbial testing kits, rapid bioburden detection assays, sterility testing media, and environmental monitoring swabs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.